Gut Check: Are New Intestine-on-a-Chip Systems the Future of Drug Testing?
"Researchers are racing to create realistic human intestine models for better drug development. Learn about the innovative technologies that could revolutionize how we understand drug absorption and metabolism."
Developing new drugs is a complex and costly process, and predicting how a drug will behave in the human body is a major challenge. While the liver has long been considered the primary organ for drug clearance, the intestine plays a significant role in drug metabolism and interactions. This has led researchers to develop more sophisticated models that mimic the intestinal environment.
Traditional methods of studying drug absorption and metabolism have limitations. Measuring how much of a drug is absorbed (Fa) is relatively straightforward, but determining how much of the absorbed drug is broken down in the gut (Fg) before reaching the bloodstream is much harder. Existing in vitro systems often don't accurately reflect the complexity of the human intestine.
To overcome these challenges, scientists are creating advanced in vitro models that better represent the human intestine. These models, often referred to as 'intestine-on-a-chip' systems, are bio-engineered from various sources, including intestinal cells, stem cells, and tissue extracts. This article will explore the latest advancements in these models, their strengths and limitations, and how they are being used to improve drug development.
A More Mature Intestine-on-a-Chip
A 2025 gene-expression study found that differentiated intestinal epithelial cells expressed genes for digestive enzymes, nutrient transporters, and drug-metabolizing enzymes. These pathways were most enhanced in the intestine-on-a-chip, whose expression profile suggested a more mature state. Emulate's summary of the study says the Intestine-Chip showed the strongest upregulation of digestion, nutrient-transport, and drug-metabolism genes, including CYP enzymes, compared with organoids and Transwells. A separate 2025 study reported that a genome-edited intestine–liver chip could serve as a convenient, cost-effective tool for drug absorption and metabolism experiments that account for both organs.
Current Models and Their Gaps
Gut-on-a-chip systems are an in-vitro approach to studying intestinal processes, including absorption and metabolism of orally ingested drugs. A 2024 human intestine-on-a-chip standard specifies scope, terminology, technical requirements, detection methods, and quality control for building these models. However, one review notes that most current Gut-on-a-Chip approaches focus on drug metabolism in host cells and omit gut microbiota as contributors to drug transformation and epithelial metabolic regulation, limiting their use for studying intestinal first-pass metabolism. The supplied article description also observes that traditional drug testing often fails to predict how medications behave in the human body.
From Drug-Development Reviews to Integrated Chips
A 2023 review examined how gut-on-a-chip design affects preclinical studies of oral bioavailability and intestinal disease. It emphasized the gut's role in absorption and metabolism of orally ingested drugs, as well as growing interest in characterizing intestinal disease processes. A later milestone reported on November 4, 2025, was a genome-edited intestine–liver chip for integrated evaluation of intestinal and hepatic drug absorption and metabolism. Its reported results supported the chip's potential as a convenient, cost-effective tool for these experiments.
Beyond the Petri Dish: How New Intestinal Models Are Improving Drug Development
Researchers are exploring various ways to create more realistic models of the human intestine. These approaches include:
- Enteroids: These 'mini-intestines' are grown from intestinal stem cells and can differentiate into various intestinal cell types. While they mimic intestinal cell structure, they lack accessibility to the inner compartment and are difficult to scale up for high-throughput drug screening.
- Enterocytes: These isolated intestinal cells can be cryopreserved for long-term storage and used to study drug metabolism. However, they may not fully represent the function of transporters and DMEs.
- iPSCs: Stem-cell derived enterocytes can be tailored with growth factors and small-molecule enhancements and may enable high throughput. However, their lack of certain key DME expression limits drug disposition predictions.
- Microfluidics-based platforms: These systems use fluid flow and mechanical forces to mimic the intestinal environment. However, most are derived from Caco-2 cell lines that have low CYP3A expressions.
- Human primary cell derived intestinal models: Micro-tissue systems leverage healthy ileal epithelial cells and fibroblasts, differentiated in high throughput wells. These closely simulate the metabolic features of the human ileum.
A Broader Toolkit for Enteric Drug Research
A review of in-vitro human cell-based experimental models focuses on enteric drug metabolism and the potential for interactions involving drugs and natural products. A proof-of-concept study explored canine intestinal organoids as a model of intestinal drug permeability, describing 3D organoids as a reasonably affordable system that can avoid more invasive live-animal assays. Another study compared Caco-2 cells with primary human jejunal (J2) and duodenal (D109) enteroid-derived cells in the OrganoPlate 3-lane 40 microphysiological system and static 24-well Transwells. A separate review traces gut-on-a-chip development from simple monocultures to bi- and tri-culture systems for studying drug metabolism, disease, and gut–microbiome interactions.
Adoption Has Not Reached Drug Pipelines
A February 5, 2026, article describes the FDA's plan to phase out animal-testing requirements for drug assessments in light of advances in new approach methodologies, including human Organ Chip microfluidic culture technology. It also reports an important limitation: although Organ Chips are being explored in many pharmaceutical laboratories, they have not yet been integrated into drug-development pipelines. The source therefore presents regulatory interest and laboratory exploration alongside a gap in pipeline adoption.
Chip-Based and Well-Based Absorption Models
A 2025 study on gut-on-a-chip drug absorption models states that conventional well-based in-vitro cell models do not accurately simulate drug absorption through the intestinal epithelium. The authors developed a gut-on-a-chip to observe drug absorption and positioned chip-based models as an alternative receiving growing attention. The supplied comparative source on monoclonal antibody HAb 18 reports that its F(ab')₂ fragment had pharmacokinetics similar to its Fab fragment and fit a two-compartment pharmacokinetic model; it does not compare those fragments with an intestine-on-a-chip.
The Future of Drug Development: Building Better Intestinal Models
The development of more sophisticated intestinal models holds great promise for improving drug development. These models can help researchers:
The Case for Patient-Specific Intestinal Metabolism
A July 23, 2026, article on engineering human Gut-on-a-Chip culturomics argues for better modeling of intestinal drug metabolism in a patient-specific manner. Its stated concern is that research focused solely on hepatic processes misses this need. This supports treating intestinal metabolism as a distinct part of drug evaluation, while the source frames patient-specific modeling as a critical need rather than a settled solution.
Connecting Intestinal Models to Human Health
A 2020 review describes gut-on-chip systems and their applications in drug pharmacokinetics, host–gut microbiota crosstalk, and nutrition metabolism. These areas connect laboratory models to questions about how drugs are handled, how the host and gut microbes interact, and how nutrients are processed. The review presents these as research applications of in-vitro systems.
<ul> <li>Better predict drug absorption and metabolism in humans</li> <li>Identify potential drug-drug interactions</li> <li>Optimize drug formulations to improve bioavailability</li> <li>Reduce the risk of drug failure in clinical trials</li> </ul>
To fully realize the potential of these models, researchers need to focus on several key areas. This includes improving the accuracy of DME and transporter expression, optimizing culture conditions, and developing methods for scaling up production. By addressing these challenges, we can create more reliable and predictive models that will ultimately lead to safer and more effective drugs.